Protalix director awarded 17K options, 8.5K RSUs

A Protalix BioTherapeutics director received new stock options and RSU awards that vest quarterly over three years.

Rhea-AI Filing Summary

Protalix BioTherapeutics, Inc. (PLX) reported that director Pol F. Boudes received equity compensation on September 3, 2026, consisting of options to purchase 17,000 shares of common stock at an exercise price of $2.59 per share, expiring September 3, 2036, and 8,500 restricted stock units.

The options and RSUs each vest in 12 equal quarterly installments, beginning on the grant date. Each RSU represents the right to receive one share of common stock upon vesting. No Rule 10b5-1 trading plan is reported in connection with these awards.

Insider Trade Summary

Grant/Award: 25,500 shares

Grant/Award 2 txns

Insider Boudes Pol F

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (Right to Buy) F1, F2	17,000	$0.00	$0.00
Grant/Award	Restricted Stock Units F3, F4	8,500	$0.00	$0.00

Holdings After Transaction: Stock Options (Right to Buy) — 17,000 contracts (Direct); Restricted Stock Units — 8,500 contracts (Direct)

Footnotes (4)

1. F1. The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant.
2. F2. Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030, (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032, (iii) options to purchase 61,676 shares of common stock at an exercise price equal to $1.66 per share that expire on September 29, 2033, and (iv) options to purchase 15,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035.
3. F3. Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock.
4. F4. The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant.

Key Figures

New stock options granted: 17,000 options Option exercise price: $2.59 per share Option expiration date: September 3, 2036 +4 more

7 metrics

New stock options granted 17,000 options Options to purchase common stock granted to director Pol F. Boudes on September 3, 2026

Option exercise price $2.59 per share Exercise price for the 17,000 stock options granted September 3, 2026

Option expiration date September 3, 2036 Expiration date for the 17,000 stock options granted to Pol F. Boudes

Restricted stock units granted 8,500 RSUs RSUs granted to Pol F. Boudes on September 3, 2026

Vesting schedule length 12 quarterly installments Vesting pattern for both the new stock options and RSUs

Additional option grant 1 40,000 options at $3.55 per share Existing options expiring January 20, 2030, noted as not included in the new post-transaction total

Additional option grant 2 50,000 options at $1.03 per share Existing options expiring September 7, 2032, noted as not included in the new post-transaction total

Key Terms

Restricted Stock Units, exercise price, vesting, quarterly installments

4 terms

Restricted Stock Units financial

"Each restricted stock unit (RSU) represents the right to receive, following vesting, one share"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

exercise price financial

"options to purchase 40,000 shares of common stock at an exercise price equal to $3.55"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The shares of common stock underlying the RSUs vest in 12 equal quarterly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

quarterly installments financial

"vest in 12 equal quarterly installments commencing upon the date of grant"

FAQ

What equity awards did Protalix BioTherapeutics (PLX) grant to director Pol F. Boudes?

Protalix BioTherapeutics granted Pol F. Boudes options for 17,000 shares of common stock at $2.59 per share, expiring September 3, 2036, and 8,500 restricted stock units, all awarded on September 3, 2026.

How do the new stock options for PLX director Pol F. Boudes vest?

The options for 17,000 shares of Protalix BioTherapeutics common stock vest in 12 equal quarterly installments starting on the September 3, 2026 grant date.

What are the terms of the restricted stock units granted by PLX on September 3, 2026?

Protalix BioTherapeutics granted 8,500 restricted stock units to Pol F. Boudes. Each RSU represents the right to receive one share of common stock after vesting and vests in 12 equal quarterly installments starting on the grant date.

What is the exercise price and expiration date of the new PLX stock options?

The new options granted to Pol F. Boudes have an exercise price of $2.59 per share and expire on September 3, 2036.

Were the PLX equity grants to Pol F. Boudes made under a Rule 10b5-1 plan?

No. The filing indicates that these equity awards to Pol F. Boudes were not made pursuant to a Rule 10b5-1 trading plan.

Does Pol F. Boudes hold other Protalix BioTherapeutics options besides the new grant?

Yes. A footnote lists additional options for 40,000, 50,000, 61,676, and 15,000 shares with exercise prices between $1.03 and $3.55, expiring from January 20, 2030 through September 3, 2035.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/04/2026 - 06:04 AM Accepted by SEC EDGAR 09/04/2026 - 06:00 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Boudes Pol F

(Last) (First) (Middle)

C/O PROTALIX BIOTHERAPEUTICS, INC.

2 SNUNIT STREET SCIENCE PARK, POB 455

(Street)

CARMIEL 2161401

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
Protalix BioTherapeutics, Inc. [ PLX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)	$2.59	09/03/2026		A		17,000		(1)	09/03/2036	Common Stock	17,000	$0	17,000(2)	D
Restricted Stock Units	(3)	09/03/2026		A		8,500		(4)	(4)	Common Stock	8,500	$0	8,500	D

Explanation of Responses:

1. The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant.

2. Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030, (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032, (iii) options to purchase 61,676 shares of common stock at an exercise price equal to $1.66 per share that expire on September 29, 2033, and (iv) options to purchase 15,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035.

3. Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock.

4. The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant.

	/s/ Joseph R. Magnas, Attorney-in-Fact	09/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)